Axcella Health (NASDAQ:AXLA) Lowered to Sell at Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Axcella Health (NASDAQ:AXLA) from a hold rating to a sell rating in a report released on Monday morning, Zacks.com reports.

According to Zacks, “Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company’s principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical stage. Axcella Health Inc. is based in Cambridge, Massachusetts. “

Several other research analysts have also recently weighed in on the stock. Goldman Sachs Group began coverage on shares of Axcella Health in a report on Sunday, June 2nd. They issued a buy rating and a $25.00 price target for the company. JPMorgan Chase & Co. began coverage on shares of Axcella Health in a report on Monday, June 3rd. They issued an overweight rating and a $20.00 price target for the company. Svb Leerink began coverage on shares of Axcella Health in a report on Monday, June 3rd. They issued an outperform rating and a $21.00 price target for the company. Finally, Leerink Swann began coverage on shares of Axcella Health in a report on Monday, June 3rd. They issued an outperform rating for the company. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Axcella Health has an average rating of Buy and a consensus price target of $22.00.

Axcella Health stock opened at $6.19 on Monday. Axcella Health has a twelve month low of $6.10 and a twelve month high of $15.99. The company has a quick ratio of 17.42, a current ratio of 17.42 and a debt-to-equity ratio of 0.27. The firm has a 50 day moving average of $7.37.

Axcella Health (NASDAQ:AXLA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.31). As a group, equities research analysts predict that Axcella Health will post -3.82 EPS for the current fiscal year.

In other Axcella Health news, Director David R. Epstein acquired 6,941 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were acquired at an average price of $7.00 per share, with a total value of $48,587.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David R. Epstein acquired 4,556 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was acquired at an average cost of $8.76 per share, for a total transaction of $39,910.56. The disclosure for this purchase can be found here. Insiders bought 53,293 shares of company stock valued at $392,282 in the last quarter.

Hedge funds have recently made changes to their positions in the company. Artal Group S.A. bought a new stake in shares of Axcella Health in the second quarter worth $3,628,000. Harbourvest Partners LLC bought a new stake in shares of Axcella Health in the second quarter worth $11,442,000. BlackRock Inc. bought a new stake in shares of Axcella Health in the second quarter worth $667,000. Vanguard Group Inc. bought a new stake in shares of Axcella Health in the second quarter worth $499,000. Finally, Tower Research Capital LLC TRC bought a new stake in shares of Axcella Health in the second quarter worth $122,000. 62.26% of the stock is currently owned by institutional investors and hedge funds.

About Axcella Health

There is no company description available for Axcella Health Inc

Featured Article: Dead Cat Bounce

Get a free copy of the Zacks research report on Axcella Health (AXLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report